Sanofi/Regeneron win 1st US PCSK9 OK with Praluent
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron Pharmaceuticals on 24 July pulled off the first US approval of a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor – gaining the FDA's nod for Praluent (alirocumab).
You may also be interested in...
Regeneron/Sanofi, Amgen PCSK9 Rivalry Continues, But Not In US Courts
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
10 Drug Launch Flops Of The Decade
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.